# A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin

Study · id `cardio:ct-nct01570751` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01570751](<https://clinicaltrials.gov/study/NCT01570751>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01570751

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 145 participants.

## Technical summary

Registry record NCT01570751. Randomized; no masking; primary purpose treatment. Start 2012-04 (registry gives no type); primary completion 2014-01 (actual). Results posted on 2015-11-18.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 145 participants (enrolled count; ClinicalTrials.gov record NCT01570751, source copy `cardio:ctgov-nct01570751-2017-03-07`, retrieved 2026-10-26)
- Start date: 2012-04 (registry gives no type) (ClinicalTrials.gov record NCT01570751, source copy `cardio:ctgov-nct01570751-2017-03-07`, retrieved 2026-10-26)
- Primary completion: 2014-01 (actual) (ClinicalTrials.gov record NCT01570751, source copy `cardio:ctgov-nct01570751-2017-03-07`, retrieved 2026-10-26)
- Completion: 2014-01 (actual) (ClinicalTrials.gov record NCT01570751, source copy `cardio:ctgov-nct01570751-2017-03-07`, retrieved 2026-10-26)
- Results first posted: 2015-11-18 (ClinicalTrials.gov record NCT01570751, source copy `cardio:ctgov-nct01570751-2017-03-07`, retrieved 2026-10-26)
- Countries: United States; Puerto Rico (ClinicalTrials.gov record NCT01570751, source copy `cardio:ctgov-nct01570751-2017-03-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01570751-2017-03-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): insulin degludec
- Intervention (Drug): insulin glargine
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Patient-reported outcomes from a randomized, crossover trial comparing a pen injector with insulin degludec versus a pen injector with insulin glargine U100 in patients with type 2 diabetes (`cardio:pubmed-30974973`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 77f680d3985c4db8bdfd1638aa5c26342415d931e618b956e1ea19d603db9798
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
